Baptist Heart & Vascular Institute Research

Latest Research:
June 2023

The Baptist Heart & Vascular Institute research goal is to enhance patient care by offering access to the newest treatment alternatives.

The research department is conducting a study to investigate the efficacy of an investigational FXIa in the prevention of stroke and systemic embolism and its bleeding risk when compared to apixaban in subjects with atrial fibrillation. Phase 2 studies showed the investigational drug had less bleeding when compared to apixaban and was well tolerated with no additional safety signals identified regarding general safety, laboratory assessments or EKGs. Subjects are randomized to investigational drug once a day or apixaban 5 mg or 2.5 mg twice a day.

Research is also involved with an acute coronary syndrome study, which is assessing the efficacy of an investigational P2Y12 receptor antagonist that is self-administered upon occurrence of symptoms suggestive of an AMI in subjects at risk of having a recurrent AMI. Phase 1 and 2 studies showed that the investigational drug was suitable for early intervention by targeting the formation of a coronary thrombus while it is still platelet rich, thereby aborting an AMI at its onset. The study drug is administered subcutaneously by the subject and provides platelet inhibition sustained for at least eight hours with full recovery of pre-injection platelet function observed 24 hours post-injection. The novel approach offers subjects the opportunity to act early while they are waiting for medical assistance.

If you would like additional information about Baptist Heart & Vascular Institute’s research program, please call  448.227.6690.